docs/_posts/Ahmetemintek/2022-04-01-normalized_section_header_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-04-04-normalized_section_header_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-05-11-abbreviation_mapper_en_3_0.md
docs/_posts/Cabir40/2022-03-03-clinical_deidentification_en_2_4.md
docs/_posts/Cabir40/2022-03-03-clinical_deidentification_en_3_0.md
docs/_posts/Cabir40/2022-03-23-assertion_dl_biobert_scope_L10R10_en_3_0.md
docs/_posts/Cabir40/2022-03-24-assertion_dl_biobert_scope_L10R10_en_2_4.md
docs/_posts/Cabir40/2022-04-01-explain_clinical_doc_medication_en_3_0.md
docs/_posts/Cabir40/2022-05-10-sbiobertresolve_cpt_procedures_measurements_augmented_en_3_0.md
docs/_posts/Cabir40/2022-05-11-sbiobertresolve_icd10cm_slim_billable_hcc_en_3_0.md
docs/_posts/Cabir40/2022-05-12-sbiobertresolve_icd10cm_slim_normalized_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-03-22-bert_token_classifier_drug_development_trials_en_3_0.md
docs/_posts/Meryem1425/2022-03-21-bert_token_classifier_ner_jsl_en_2_4.md
docs/_posts/bunyamin-polat/2022-03-22-bert_token_classifier_drug_development_trials_en_2_4.md
docs/_posts/gadde5300/2022-02-09-bert_token_classifier_ner_supplement_en.md
docs/_posts/gadde5300/2022-03-01-bert_sequence_classifier_rct_biobert_en_2_4.md
docs/_posts/gadde5300/2022-03-01-bert_sequence_classifier_rct_biobert_en_3_0.md
docs/_posts/gadde5300/2022-03-17-assertion_dl_scope_L10R10_en_2_4.md
docs/_posts/gadde5300/2022-03-17-assertion_dl_scope_L10R10_en_3_0.md
docs/_posts/gadde5300/2022-04-24-rct_binary_classifier_use_en_3_0.md
docs/_posts/gadde5300/2022-04-25-bert_sequence_classifier_binary_rct_biobert_en_3_0.md
docs/_posts/gadde5300/2022-04-25-bert_sequence_classifier_binary_rct_biobert_pipeline_en_3_0.md
docs/_posts/gadde5300/2022-04-25-rct_binary_classifier_biobert_en_3_0.md
docs/_posts/gadde5300/2022-04-25-rct_binary_classifier_biobert_pipeline_en_3_0.md
docs/_posts/gadde5300/2022-04-25-rct_binary_classifier_use_pipeline_en_3_0.md
docs/_posts/galiph/2022-03-03-german_deid_pipeline_spark24_de_2_4.md
docs/_posts/galiph/2022-04-18-sbiobertresolve_ndc_en_2_4.md
docs/_posts/galiph/2022-05-08-rxnorm_action_treatment_mapper_en_3_0.md
docs/_posts/galiph/2022-05-09-rxnorm_ndc_mapper_en_3_0.md
docs/_posts/galiph/2022-05-11-drug_brandname_ndc_mapper_en_3_0.md
docs/_posts/josejuanmartinez/2022-02-15-ner_deid_generic_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-15-ner_deid_generic_roberta_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-15-ner_deid_subentity_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-15-ner_deid_subentity_roberta_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-16-ner_deid_generic_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-16-ner_deid_generic_roberta_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-16-ner_deid_subentity_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-16-ner_deid_subentity_roberta_augmented_es.md
docs/_posts/josejuanmartinez/2022-04-05-re_zeroshot_biobert_en_3_0.md
docs/_posts/josejuanmartinez/2022-04-13-ner_deid_generic_pt_3_0.md
docs/_posts/josejuanmartinez/2022-04-13-ner_deid_subentity_pt_3_0.md
docs/_posts/luca-martial/2022-02-08-bert_sequence_classifier_ade_en.md
docs/_posts/luca-martial/2022-02-08-bert_sequence_classifier_gender_biobert_en.md
docs/_posts/luca-martial/2022-02-08-distilbert_sequence_classifier_ade_en.md
docs/_posts/luca-martial/2022-02-11-ner_deid_generic_fr.md
docs/_posts/luca-martial/2022-02-11-ner_deid_subentity_fr.md
docs/_posts/luca-martial/2022-02-14-ner_deid_subentity_fr.md
docs/_posts/luca-martial/2022-03-22-ner_deid_subentity_it_3_0.md
docs/_posts/luca-martial/2022-03-25-ner_deid_generic_it_2_4.md
docs/_posts/luca-martial/2022-03-25-ner_deid_generic_it_3_0.md
docs/_posts/luca-martial/2022-03-25-ner_deid_subentity_it_2_4.md
docs/_posts/murat-gunay/2022-03-09-bert_token_classifier_ner_cellular_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-10-bert_token_classifier_ner_cellular_pipeline_en_2_4.md
docs/_posts/murat-gunay/2022-03-21-ner_radiology_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_radiology_wip_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_risk_factors_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_risk_factors_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-22-ner_ade_healthcare_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-22-ner_events_healthcare_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-22-ner_healthcare_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-22-ner_posology_healthcare_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-23-bert_token_classifier_drug_development_trials_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-23-bert_token_classifier_ner_jsl_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_bodypart_directions_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_bodypart_proceduretest_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_date_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_test_problem_finding_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_test_result_date_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-04-11-spellcheck_clinical_en_3_0.md
docs/_posts/murat-gunay/2022-04-13-spellcheck_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-04-14-spellcheck_clinical_en_2_4.md
docs/_posts/murat-gunay/2022-04-14-spellcheck_clinical_pipeline_en_2_4.md
docs/_posts/murat-gunay/2022-04-18-spellcheck_clinical_en_2_4.md
docs/_posts/murat-gunay/2022-04-19-spellcheck_clinical_pipeline_en_2_4.md
docs/_posts/murat-gunay/2022-05-10-ner_biomedical_bc2gm_en_3_0.md
docs/_posts/murat-gunay/2022-05-11-ner_biomedical_bc2gm_en_2_4.md
docs/_posts/Ahmetemintek/2022-04-01-normalized_section_header_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-04-04-normalized_section_header_mapper_en_3_0.md
docs/_posts/Ahmetemintek/2022-05-11-abbreviation_mapper_en_3_0.md
docs/_posts/Cabir40/2022-03-03-clinical_deidentification_en_2_4.md
docs/_posts/Cabir40/2022-03-03-clinical_deidentification_en_3_0.md
docs/_posts/Cabir40/2022-03-23-assertion_dl_biobert_scope_L10R10_en_3_0.md
docs/_posts/Cabir40/2022-03-24-assertion_dl_biobert_scope_L10R10_en_2_4.md
docs/_posts/Cabir40/2022-04-01-explain_clinical_doc_medication_en_3_0.md
docs/_posts/Cabir40/2022-05-10-sbiobertresolve_cpt_procedures_measurements_augmented_en_3_0.md
docs/_posts/Cabir40/2022-05-11-sbiobertresolve_icd10cm_slim_billable_hcc_en_3_0.md
docs/_posts/Cabir40/2022-05-12-sbiobertresolve_icd10cm_slim_normalized_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-03-22-bert_token_classifier_drug_development_trials_en_3_0.md
docs/_posts/Meryem1425/2022-03-21-bert_token_classifier_ner_jsl_en_2_4.md
docs/_posts/bunyamin-polat/2022-03-22-bert_token_classifier_drug_development_trials_en_2_4.md
docs/_posts/gadde5300/2022-02-09-bert_token_classifier_ner_supplement_en.md
docs/_posts/gadde5300/2022-03-01-bert_sequence_classifier_rct_biobert_en_2_4.md
docs/_posts/gadde5300/2022-03-01-bert_sequence_classifier_rct_biobert_en_3_0.md
docs/_posts/gadde5300/2022-03-17-assertion_dl_scope_L10R10_en_2_4.md
docs/_posts/gadde5300/2022-03-17-assertion_dl_scope_L10R10_en_3_0.md
docs/_posts/gadde5300/2022-04-24-rct_binary_classifier_use_en_3_0.md
docs/_posts/gadde5300/2022-04-25-bert_sequence_classifier_binary_rct_biobert_en_3_0.md
docs/_posts/gadde5300/2022-04-25-bert_sequence_classifier_binary_rct_biobert_pipeline_en_3_0.md
docs/_posts/gadde5300/2022-04-25-rct_binary_classifier_biobert_en_3_0.md
docs/_posts/gadde5300/2022-04-25-rct_binary_classifier_biobert_pipeline_en_3_0.md
docs/_posts/gadde5300/2022-04-25-rct_binary_classifier_use_pipeline_en_3_0.md
docs/_posts/galiph/2022-03-03-german_deid_pipeline_spark24_de_2_4.md
docs/_posts/galiph/2022-04-18-sbiobertresolve_ndc_en_2_4.md
docs/_posts/galiph/2022-05-08-rxnorm_action_treatment_mapper_en_3_0.md
docs/_posts/galiph/2022-05-09-rxnorm_ndc_mapper_en_3_0.md
docs/_posts/galiph/2022-05-11-drug_brandname_ndc_mapper_en_3_0.md
docs/_posts/josejuanmartinez/2022-02-15-ner_deid_generic_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-15-ner_deid_generic_roberta_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-15-ner_deid_subentity_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-15-ner_deid_subentity_roberta_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-16-ner_deid_generic_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-16-ner_deid_generic_roberta_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-16-ner_deid_subentity_augmented_es.md
docs/_posts/josejuanmartinez/2022-02-16-ner_deid_subentity_roberta_augmented_es.md
docs/_posts/josejuanmartinez/2022-04-05-re_zeroshot_biobert_en_3_0.md
docs/_posts/josejuanmartinez/2022-04-13-ner_deid_generic_pt_3_0.md
docs/_posts/josejuanmartinez/2022-04-13-ner_deid_subentity_pt_3_0.md
docs/_posts/luca-martial/2022-02-08-bert_sequence_classifier_ade_en.md
docs/_posts/luca-martial/2022-02-08-bert_sequence_classifier_gender_biobert_en.md
docs/_posts/luca-martial/2022-02-08-distilbert_sequence_classifier_ade_en.md
docs/_posts/luca-martial/2022-02-11-ner_deid_generic_fr.md
docs/_posts/luca-martial/2022-02-11-ner_deid_subentity_fr.md
docs/_posts/luca-martial/2022-02-14-ner_deid_subentity_fr.md
docs/_posts/luca-martial/2022-03-22-ner_deid_subentity_it_3_0.md
docs/_posts/luca-martial/2022-03-25-ner_deid_generic_it_2_4.md
docs/_posts/luca-martial/2022-03-25-ner_deid_generic_it_3_0.md
docs/_posts/luca-martial/2022-03-25-ner_deid_subentity_it_2_4.md
docs/_posts/murat-gunay/2022-03-09-bert_token_classifier_ner_cellular_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-10-bert_token_classifier_ner_cellular_pipeline_en_2_4.md
docs/_posts/murat-gunay/2022-03-21-ner_radiology_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_radiology_wip_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_risk_factors_biobert_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-21-ner_risk_factors_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-22-ner_ade_healthcare_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-22-ner_events_healthcare_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-22-ner_healthcare_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-22-ner_posology_healthcare_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-23-bert_token_classifier_drug_development_trials_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-23-bert_token_classifier_ner_jsl_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_bodypart_directions_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_bodypart_proceduretest_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_date_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_test_problem_finding_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-03-31-re_test_result_date_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-04-11-spellcheck_clinical_en_3_0.md
docs/_posts/murat-gunay/2022-04-13-spellcheck_clinical_pipeline_en_3_0.md
docs/_posts/murat-gunay/2022-04-14-spellcheck_clinical_en_2_4.md
docs/_posts/murat-gunay/2022-04-14-spellcheck_clinical_pipeline_en_2_4.md
docs/_posts/murat-gunay/2022-04-18-spellcheck_clinical_en_2_4.md
docs/_posts/murat-gunay/2022-04-19-spellcheck_clinical_pipeline_en_2_4.md
docs/_posts/murat-gunay/2022-05-10-ner_biomedical_bc2gm_en_3_0.md
docs/_posts/murat-gunay/2022-05-11-ner_biomedical_bc2gm_en_2_4.md
